Marla Dubinsky

2.0k total citations · 1 hit paper
89 papers, 919 citations indexed

About

Marla Dubinsky is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Marla Dubinsky has authored 89 papers receiving a total of 919 indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Genetics, 42 papers in Epidemiology and 26 papers in Surgery. Recurrent topics in Marla Dubinsky's work include Inflammatory Bowel Disease (57 papers), Microscopic Colitis (39 papers) and Eosinophilic Esophagitis (14 papers). Marla Dubinsky is often cited by papers focused on Inflammatory Bowel Disease (57 papers), Microscopic Colitis (39 papers) and Eosinophilic Esophagitis (14 papers). Marla Dubinsky collaborates with scholars based in United States, Canada and Spain. Marla Dubinsky's co-authors include Inga Peter, Anthony Wang, Naijun Chen, Andrew Park, Susan Bressman, H Patriquin, George Marx, Denise Herzog, Ernest G. Seidman and Josée Dubois and has published in prestigious journals such as Gastroenterology, Annals of Surgery and Gut.

In The Last Decade

Marla Dubinsky

79 papers receiving 903 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Anti–Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease

2018 286 citations Inga Peter, Marla Dubinsky et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marla Dubinsky United States	10	490	348	295	179	125	89	919
Sumihisa Kubota Japan	24	219 0.4×	98 0.3×	231 0.8×	45 0.3×	12 0.1×	54	1.5k
Katalin Eszter Müller Hungary	12	175 0.4×	119 0.3×	184 0.6×	12 0.1×	24 0.2×	51	491
Mirjana Stojković Serbia	16	73 0.1×	131 0.4×	164 0.6×	36 0.2×	25 0.2×	84	832
Jeannine M. Heckmann South Africa	22	65 0.1×	162 0.5×	87 0.3×	880 4.9×	62 0.5×	74	1.4k
Glenn Neil-Dwyer United Kingdom	12	64 0.1×	188 0.5×	145 0.5×	473 2.6×	11 0.1×	17	891
Elizabeth M. Angus United Kingdom	11	54 0.1×	55 0.2×	133 0.5×	60 0.3×	31 0.2×	20	499
V. Speranza Italy	18	94 0.2×	180 0.5×	364 1.2×	67 0.4×	7 0.1×	56	799
Fernando Tavarela Veloso Portugal	11	473 1.0×	452 1.3×	254 0.9×	7 0.0×	34 0.3×	20	818
Gregory Goodwin United States	11	78 0.2×	210 0.6×	74 0.3×	86 0.5×	4 0.0×	16	676
Émilie Duchalais France	17	55 0.1×	37 0.1×	454 1.5×	36 0.2×	25 0.2×	67	869

Countries citing papers authored by Marla Dubinsky

Since Specialization

Citations

This map shows the geographic impact of Marla Dubinsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marla Dubinsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marla Dubinsky more than expected).

Fields of papers citing papers by Marla Dubinsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marla Dubinsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marla Dubinsky. The network helps show where Marla Dubinsky may publish in the future.

Co-authorship network of co-authors of Marla Dubinsky

This figure shows the co-authorship network connecting the top 25 collaborators of Marla Dubinsky. A scholar is included among the top collaborators of Marla Dubinsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marla Dubinsky. Marla Dubinsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Panaccione, Remo, Édouard Louis, Jean–Frédéric Colombel, et al.. (2025). Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies. Journal of Crohn s and Colitis. 19(1). 5 indexed citations

Mahadevan, Uma, Cynthia H. Seow, Eleanor Barnes, et al.. (2025). Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease. Alimentary Pharmacology & Therapeutics. 62(11-12). 1125–1180.

Mahadevan, Uma, Cynthia H. Seow, Edward L. Barnes, et al.. (2025). Global consensus statement on the management of pregnancy in inflammatory bowel disease. Gut. 75(2). 208–251. 1 indexed citations

Jairath, Vipul, Geert D’Haens, Bruce E. Sands, et al.. (2025). Bowel Urgency in Crohn’s Disease: Effects of Mirikizumab in a Randomized Controlled Phase 3 Study. Clinical Gastroenterology and Hepatology. 24(2). 463–473.e5.

Hunter, Theresa, Carolyn Sweeney, Daniel Wolin, et al.. (2024). Evaluation of the Symptoms and Clinical Characteristics of Crohn’s Disease and Ulcerative Colitis That Affect Healthcare Providers’ Treatment Choices. Crohn s & Colitis 360. 6(4). otae053–otae053.

Danese, Silvio, Julián Panés, Marla Dubinsky, et al.. (2024). Review: Risk Stratification of Patients With Ulcerative Colitis for Treatment With Tofacitinib. Crohn s & Colitis 360. 6(4). otae049–otae049. 2 indexed citations

Travis, Simon, Tadakazu Hisamatsu, Monika Fischer, et al.. (2024). OP12 Mirikizumab improves fatigue, bowel urgency, and quality of life in patients with moderately to severely active Crohn’s Disease: Results from a phase 3 clinical trial. Journal of Crohn s and Colitis. 18(Supplement_1). i21–i23. 5 indexed citations

Vermeire, Séverine, Marla Dubinsky, Brian Feagan, et al.. (2024). P113 Maintenance of week 12 response through week 52 with etrasimod in patients with ulcerative colitis in ELEVATE UC 52. Poster presentations. A119.1–A119.

Bourgonje, Arno R., Carmen Argmann, Bruce E. Sands, et al.. (2024). DOP33 Distinct perturbances in metabolic pathways associate with disease progression in patients with Inflammatory Bowel Disease. Journal of Crohn s and Colitis. 18(Supplement_1). i131–i133. 1 indexed citations

10.

Basnyat, Buddha, et al.. (2024). P671 Patient perspectives on symptoms and impacts in Crohn’s disease: Results from qualitative research. Journal of Crohn s and Colitis. 18(Supplement_1). i1265–i1266. 1 indexed citations

11.

Travis, Simon, Alison Potts Bleakman, Marla Dubinsky, et al.. (2023). P507 United States and European patient perspectives on the impact of moderate-to-severe Ulcerative Colitis on sexual activity: Communicating Needs and Features of IBD Experiences (CONFIDE) survey. Journal of Crohn s and Colitis. 17(Supplement_1). i637–i639. 1 indexed citations

12.

Dubinsky, Marla, Min Yang, Mirko Fillbrunn, et al.. (2022). S1028 Symptoms and Laboratory Values as Proxies for Endoscopic and Histologic Clinical Endpoints in Ulcerative Colitis: A Mediation Analysis Based on Upadacitinib Phase 3 Induction Trials. The American Journal of Gastroenterology. 117(10S). e746–e746. 1 indexed citations

13.

Yarur, Andrés, Dermot McGovern, María T. Abreu, et al.. (2022). Combination Therapy With Immunomodulators Improves the Pharmacokinetics of Infliximab But Not Vedolizumab or Ustekinumab. Clinical Gastroenterology and Hepatology. 21(11). 2908–2917.e10. 17 indexed citations

14.

Torres, Joana, Jonas Halfvarson, Iago Rodríguez–Lago, et al.. (2021). Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD—Prediction and Prevention of Inflammatory Bowel Disease. Journal of Crohn s and Colitis. 15(9). 1443–1454. 42 indexed citations

15.

Chen, Xin, Joanne Lai, Ying Song, et al.. (2021). Butanol Purified Food Allergy Herbal Formula-2 Has an Immunomodulating Effect ex-vivo in Pediatric Crohn's Disease Subjects. Frontiers in Medicine. 8. 782859–782859. 1 indexed citations

16.

Nair, N., Christine Austin, Paul Curtin, et al.. (2020). Association Between Early-life Exposures and Inflammatory Bowel Diseases, Based on Analyses of Deciduous Teeth. Gastroenterology. 159(1). 383–385. 20 indexed citations

17.

Dubinsky, Marla, Andrew G. Bushmakin, Marco DiBonaventura, et al.. (2019). Sa1872 – Measuring the Mediating Effects of Tofacitinib on Health Status in Ulcerative Colitis: Data from the Octave Program. Gastroenterology. 156(6). S–437.

18.

Mahadevan, Uma, Christopher F. Martin, Christina Chambers, et al.. (2014). 1 Achievement of Developmental Milestones Among Offspring of Women With Inflammatory Bowel Disease: The PIANO Registry. Gastroenterology. 146(5). S–1. 23 indexed citations

19.

White, E.C., Gil Melmed, Eric Vasiliauskas, et al.. (2012). Does Preoperative Immunosuppression Influence Unplanned Hospital Readmission After Surgery in Patients With Crohn’s Disease?. Diseases of the Colon & Rectum. 55(5). 563–568. 16 indexed citations

20.

Berel, Dror, Stephan R. Targan, Andrew Ippoliti, et al.. (2012). 626 Patients With Ulcerative Colitis Hospitalized With Clostridium difficile Infection (CDI) Should Be Treated With Vancomycin Regardless of Cdi Severity. Gastroenterology. 142(5). S–123. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact